What is AI In Medical Imaging Market?
Medical Imaging is a technology that is used to create images of the human body to diagnose, monitor, and treat medical illness. AI can improve medical imaging processes like image analysis and help with patient diagnosis. With many applied AI solutions and many more AI applications showing promising scientific test results, the market for AI in medical imaging is forecast to grow exponentially over the next few years.
The market study is being classified, by Application (Digital Pathology, Orthopedics, Cardiology, Urology, Gastrology, Neurology and Others) and major geographies with country level break-up.
GE Healthcare (United States), IBM Corporation (United States), Philips Healthcare (United States), Samsung Electronics (South Korea), Medtronic (Ireland), Hitachi Medical Corporation (Japan), Toshiba Corporation (Japan), Echonous Inc (United States), Enlitic, Inc (United States), RapidAI (United States), oxipit (Lithuania), Siemens Healthineers AG (Germany), Intel Corporation (United States) and Nvidia Corporation (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Mindray Medical International (China), Planmed Oy (Finland), CurveBeam LLC (United States) and Shimadzu Corporation (Japan).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global AI In Medical Imaging market throughout the predicted period.
Analyst at AMA have segmented the market study of Global AI In Medical Imaging market by Type, Application and Region.
On the basis of geography, the market of AI In Medical Imaging has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Patients All-Around the Globe Due to the Prevailing COVID-19 Worldwide
- The Growing Number of Cancer Patients and Diagnostic Procedures
- The Adoption of Augmented and Virtual Reality in Medical Imaging
- The High Installation Cost Involved in Medical Imaging Instrument
- Investments in Technological Advancement in Healthcare Infrastructures
- Growing Development of Healthcare Infrastructure
- Stringent Government Laws Associated with Equipment and Machines used in Medical Imaging
- Lack of Awareness about AI in Medical Imaging Advantages among People
Market Leaders and some development strategies
In Aug 2020, The National Institutes of Health has launched the Medical Imaging and Data Resource Center (MIDRC), an ambitious effort that will harness the power of artificial intelligence and medical imaging to fight COVID-19., and In Jan 2020, Oxipit announced a partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria. The partnership aims to introduce vanguard AI diagnostic capabilities and improve the detection of 75 pathologies, including tuberculosis, to one of the largest markets in Africa.
In Dec 2019, GE Healthcare launched more than 30 new, imaging intelligent applications and smart devices designed to drive efficiency in radiology departments, aiming to double productivity and cost savings for systems by 2025., and In Dec 2019, RAPID is now available and installed in Vietnam. The RAPID artificial intelligence framework helps to quantify brain lesions and extend the window of potential stroke intervention from six hours after onset to up to 24 hours, for patients with salvageable brain tissue.
"Devices used in medical imaging are considered medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Medical Device Amendments of 1976 and subsequent related amendments. Most existing medical imaging technologies are considered non-510(k)-exempt Class I and Class II medical devices by FDA, making them eligible for clearance under the 510(k) pathway. Under this pathway, new medical devices that are substantially equivalent to existing, legally marketed Class I and Class II devices in terms of intended use, indications for use, and technological characteristics may be cleared for the U.S. market. The legally marketed devices with which comparison is made are referred to as predicate devices."
Key Target Audience
AI In Medical Imaging Provider, Technology Provider, Medical Imaging Manufacturers, Medical Imaging Distributors and Suppliers, Research and Development Institutes, Potential Investors, Industry Associations and Others
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase